REVELATION BIOSCIENCES, INC. current report, Q2 FY2023

Business Context and Reporting Period

Company: Revelation Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 29, 2023
Reporting Period: Single event date (June 29, 2023)
Business Context: The filing serves as a Regulation FD disclosure to remind stockholders of the upcoming virtual Annual Meeting of Stockholders scheduled for July 7, 2023, and to urge voting participation.

Key Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a procedural notice regarding corporate governance events.

Material Changes

No material financial changes or operational updates are reported in this filing. The only material event disclosed is the scheduling and reminder of the Annual Meeting of Stockholders.

Guidance, Outlook, and Risks

Management Commentary: Management issued a press release (Exhibit 99.1) urging stockholders to vote in the upcoming Annual Meeting.
Outlook/Guidance: No forward-looking financial guidance or operational outlook is provided in this document.
Risks/Contingencies: No specific risks or contingencies are detailed in this filing.

Key Facts for Investor Verification

  • Annual Meeting Date: Friday, July 7, 2023, at 1:00 p.m. Eastern Time.
  • Meeting Format: Virtual Annual Meeting of Stockholders.
  • Trading Symbols: Common stock (REVB) and Redeemable warrants (REVBW) trade on The Nasdaq Stock Market LLC.
  • Emerging Growth Company Status: The registrant is an emerging growth company.
  • Financial Data: Investors must refer to the most recent 10-K or 10-Q filings for financial performance metrics, as this 8-K contains none.